Shield Therapeutics PLC (LON:STX)‘s stock had its “buy” rating restated by equities research analysts at FinnCap in a note issued to investors on Thursday. They presently have a GBX 270 ($3.49) price target on the stock. FinnCap’s target price suggests a potential upside of 71.43% from the company’s previous close.

STX has been the topic of a number of other research reports. Liberum Capital reaffirmed a “buy” rating and issued a GBX 245 ($3.16) price target on shares of Shield Therapeutics PLC in a research report on Thursday. Peel Hunt reaffirmed a “buy” rating and issued a GBX 220 ($2.84) price target on shares of Shield Therapeutics PLC in a research report on Thursday, July 6th.

Shares of Shield Therapeutics PLC (LON:STX) remained flat at GBX 157.50 during trading on Thursday. The stock had a trading volume of 2,500 shares. The stock’s market cap is GBX 170.10 million. The company has a 50-day moving average price of GBX 157.50 and a 200-day moving average price of GBX 163.10. Shield Therapeutics PLC has a 12 month low of GBX 152.25 and a 12 month high of GBX 177.00.

ILLEGAL ACTIVITY NOTICE: “FinnCap Reaffirms Buy Rating for Shield Therapeutics PLC (STX)” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/09/16/finncap-reaffirms-buy-rating-for-shield-therapeutics-plc-stx.html.

About Shield Therapeutics PLC

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.

Receive News & Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.